In an interview with Giustizia Magazine, published by Golfarelli Editore, our partner Barbara La Tella explores the new legal challenges facing the pharmaceutical sector and intellectual property. The analysis begins with the handling of complex cross-border cases between originator companies and generic manufacturers, explaining why many Big Pharma companies are opting out of the Unified Patent Court (UPC) to avoid the risk of a “cascading” patent invalidation. The interview then delves into the impact of the EU Pharma Package - whose extension of the Bolar exemption to pre-launch phases will accelerate generics’ access to the market.
To read the full interview featured in the special issue prepared for the 2026 International Justice Forum which will take place in Rome from October 27 to 29, click HERE.
